About: Burden of Community-Acquired Pneumonia and Unmet Clinical Needs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Burden of Community-Acquired Pneumonia and Unmet Clinical Needs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Burden of Community-Acquired Pneumonia and Unmet Clinical Needs
Creator	Ferreira-Coimbra, João Cristina, Sarda Rello,
topic	covid:baed636bd5e7f6484534be677cb61ac8027e94fd#this
Source	PMC
abstract	Community-acquired pneumonia (CAP) is the leading cause of death among infectious diseases and an important health problem, having considerable implications for healthcare systems worldwide. Despite important advances in prevention through vaccines, new rapid diagnostic tests and antibiotics, CAP management still has significant drawbacks. Mortality remains very high in severely ill patients presenting with respiratory failure or shock but is also high in the elderly. Even after a CAP episode, higher risk of death remains during a long period, a risk mainly driven by inflammation and patient-related co-morbidities. CAP microbiology has been altered by new molecular diagnostic tests that have turned viruses into the most identified pathogens, notwithstanding uncertainties about the specific role of each virus in CAP pathogenesis. Pneumococcal vaccines also impacted CAP etiology and thus had changed Streptococcus pneumoniae circulating serotypes. Pathogens from specific regions should also be kept in mind when treating CAP. New antibiotics for CAP treatment were not tested in severely ill patients and focused on multidrug-resistant pathogens that are unrelated to CAP, limiting their general use and indications for intensive care unit (ICU) patients. Similarly, CAP management could be personalized through the use of adjunctive therapies that showed outcome improvements in particular patient groups. Although pneumococcal vaccination was only convincingly shown to reduce invasive pneumococcal disease, with a less significant effect in pneumococcal CAP, it remains the best therapeutic intervention to prevent bacterial CAP. Further research in CAP is needed to reduce its population impact and improve individual outcomes.
has issue date	2020-02-18(xsd:dateTime)
bibo:doi	10.1007/s12325-020-01248-7
bibo:pmid	32072494
has license	cc-by-nc
sha1sum (hex)	baed636bd5e7f6484534be677cb61ac8027e94fd
schema:url	https://doi.org/10.1007/s12325-020-01248-7
resource representing a document's title	Burden of Community-Acquired Pneumonia and Unmet Clinical Needs
has PubMed Central identifier	PMC7140754
has PubMed identifier	32072494
schema:publication	Adv Ther
resource representing a document's body	covid:baed636bd5e7f6484534be677cb61ac8027e94fd#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/baed636bd5e7f6484534be677cb61ac8027e94fd
is schema:about of	named entity 'shock' named entity 'IMPORTANT' named entity 'HTTPS' named entity 'MORTALITY' named entity 'CAP' named entity 'antibiotics' named entity 'rapid diagnostic tests' named entity 'Uganda' named entity 'phase II trial' named entity 'bacterial pathogen' named entity 'CAP' named entity 'observational studies' named entity 'invasive pneumococcal disease' named entity 'microbiology' named entity 'CAP' named entity 'risk factors' named entity 'RCT' named entity 'pathogens' named entity 'molecular techniques' named entity '23,000' named entity 'risk factors' named entity 'renal failure' named entity 'ICU' named entity 'anti-inflammatory drugs' named entity 'pneumococcal' named entity 'polysaccharide' named entity 'drug interactions' named entity 'standard of care' named entity 'PCV13' named entity 'antibiotic resistance' named entity 'infectious disease' named entity 'CAP' named entity 'virulence factors' named entity 'clinical practice' named entity 'risk of death' named entity 'Chile' named entity 'fungi' named entity 'PCV13' named entity 'respiratory syncytial virus' named entity '1.2' named entity 'healthcare systems' named entity 'vaccination rates' named entity 'quinolone' named entity 'tetracyclines' named entity 'Central African' named entity 'Steroid' named entity 'Asian' named entity 'pneumococcal pneumonia' named entity 'pneumococcus' named entity 'outpatient' named entity 'endemic' named entity 'CAP' named entity 'prospective studies' named entity 'CAP' named entity 'CAP' named entity 'prospective study' named entity 'nasopharyngeal swabs' named entity 'virulence factors' named entity 'CAP' named entity 'steroid' named entity 'Lancet Infectious Diseases' named entity 'immunosuppressed' named entity 'CAP' named entity 'CAP' named entity 'short duration' named entity 'age-standardized rates' named entity 'CAP' named entity 'Epidemiology' named entity 'oral antibiotics' named entity 'antibiotics' named entity 'CAP' named entity 'antibiotic' named entity 'CAP' named entity 'primary care' named entity 'CAP' named entity 'antibiotics' named entity 'causing disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software